ERCC1 (%) | ||||||
---|---|---|---|---|---|---|
Parameter | n evaluable | Negative | Weak | Moderate | Strong | p value |
All cancers | 10,436 | 35.4 | 37.1 | 22.6 | 5.0 | |
Tumor stage | ||||||
pT2 | 6790 | 38.4 | 37.3 | 20.1 | 4.2 | <0.0001 |
pT3a | 2299 | 31.6 | 35.5 | 26.4 | 6.6 | |
pT3b-pT4 | 1308 | 26.4 | 38.8 | 28.5 | 6.3 | |
Gleason grade | ||||||
≤3 + 3 | 2363 | 46.3 | 34.2 | 16.5 | 3.0 | <0.0001 |
3 + 4 | 5630 | 34.7 | 37.4 | 22.9 | 5.0 | |
3 + 4 Tert.5 | 368 | 33.4 | 40.8 | 22.0 | 3.8 | |
4 + 3 | 1040 | 25.6 | 38.8 | 28.4 | 7.3 | |
4 + 3 Tert.5 | 563 | 23.4 | 40.0 | 29.1 | 7.5 | |
≥4 + 4 | 466 | 25.8 | 38.2 | 29.0 | 7.1 | |
Lymph node metastasis | ||||||
N0 | 5856 | 32.7 | 37.6 | 23.9 | 5.8 | 0.0037 |
N+ | 585 | 25.6 | 39.8 | 27.9 | 6.7 | |
Preoperative PSA level (ng/ml) | ||||||
<4 | 1293 | 32.6 | 40.5 | 21.9 | 4.9 | 0.0078 |
4–10 | 6256 | 35.2 | 37.8 | 22.1 | 4.8 | |
10–20 | 2058 | 37.5 | 33.9 | 23.5 | 5.1 | |
>20 | 714 | 35.6 | 33.9 | 24.8 | 5.7 | |
Surgical margin | ||||||
Negative | 8294 | 36.1 | 37.5 | 21.8 | 4.7 | <0.0001 |
Positive | 1953 | 32.7 | 35.5 | 25.9 | 5.9 |